Elizabeth Dayton
Family Medicine · Omaha, NENPI 1033471008
Payments from drug & device makers
Across 93 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$488
- Bayer$139
- Novo Nordisk$135
- Pfizer$113
- Amgen$94
- Novartis$81
- plus $589 from 18 others
What the payments were for
- Food & beverage$1,640100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $488 |
| Bayer | 2 | $139 |
| Novo Nordisk | 9 | $135 |
| Pfizer | 7 | $113 |
| Amgen | 6 | $94 |
| Novartis | 5 | $81 |
| Organon | 3 | $69 |
| Merck | 4 | $62 |
| Daiichi Sankyo Inc. | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 4 | $61 |
| AstraZeneca | 3 | $46 |
| Sanofi Pasteur Inc. | 3 | $42 |
| Abbott | 2 | $36 |
| Astellas Pharma US Inc | 1 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $30 |
| Boston Scientific | 1 | $24 |
| Corium, LLC | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$125
How this compares
$1,640 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $58,850 |
| XareltoRivaroxaban | 93 | $25,963 |
| JardianceEmpagliflozin | 30 | $22,352 |
| RexultiBrexpiprazole | 24 | $17,082 |
| Cinacalcet Hcl | 12 | $16,597 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $12,964 |
| OzempicSemaglutide | 11 | $10,673 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $10,286 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $9,848 |
| Duloxetine Hcl | 156 | $8,383 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,906 |
| EntrestoSacubitril/Valsartan | 21 | $6,251 |
| Atorvastatin Calcium | 400 | $5,866 |
| Gabapentin | 281 | $5,516 |
| Sevelamer Carbonate | 24 | $5,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $113 | $58,850195 claims |
| Johnson & JohnsonXarelto | $14 | $25,96393 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $13 | $17,87129 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $61 | $17,08224 claims |
| Novo NordiskOzempic | $135 | $10,67311 claims |
| NovartisEntresto | $81 | $6,25121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Omaha
- Kenneth BladOmaha$1.6M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
- Gregston NelsonOmaha$147K
- Birgit KhandalavalaOmaha$107K
- John HallgrenOmaha$94K
- Gerard StanleyOmaha$50K
- Kent JohnsonOmaha$16K
- Yongge LiuOmaha$15K
- M DadaOmaha$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.